Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep 5;25(9):1721-1723.
doi: 10.1093/neuonc/noad095.

Hemizygous CDKN2A deletion confers worse survival outcomes in IDHmut-noncodel gliomas

Emre Kocakavuk  1   2 , Kevin C Johnson  1 , Thais S Sabedot  3 , Hans Christian Reinhardt  2 , Houtan Noushmehr  3 , Roel G W Verhaak  1   4
Affiliations

Hemizygous CDKN2A deletion confers worse survival outcomes in IDHmut-noncodel gliomas

Emre Kocakavuk et al. Neuro Oncol. .
No abstract available

Keywords: CDKN2A; IDH-mutant; astrocytoma; glioma; hemizygous deletion.

PubMed Disclaimer

Conflict of interest statement

RGWV is a co-founder of Boundless Bio.

Figures

Figure 1.
Figure 1.
Distribution of CDKN2A homozygous deletion, hemizygous deletion and wild type (wt) across six IDHmut glioma cohorts. The discovery cohort consists of the GLASS DNAseq and DNA methylation profiling datasets. The validation cohort consists of the DFCI, MSKCC, and TCGA datasets, with further validation in DKFZ methylation profiling dataset. Survival analyses are specific to IDHmut-noncodel gliomas. Upper panel depicts initial cases; lower panel depicts recurrent cases. Stacked bar plots showing the total number and relative proportion of cases with CDKN2A homozygous deletion, hemizygous deletion and wt, separated by molecular subtype into columns representing IDHmut-codel and IDHmut-noncodel. Fisher’s exact test was applied as a statistical test to compare initial and recurrent gliomas. Kaplan–Meier survival plots depict overall survival probability (y-axis) and survival time (x-axis). Overall survival indicates the time from diagnosis to death or last date of follow-up as censoring. Global log-rank test was applied for comparison of 3 groups, and pairwise log-rank test was applied for comparison of 2 groups. Note that the TCGA cohort included only initial glioma cases. No survival data was available for the DKFZ cohort. GLASS, Glioma Longitudinal Analysis Consortium; DFCI, Dana-Farber Cancer Institute; MSKCC, Memorial Sloan Kettering Cancer Center; TCGA, The Cancer Genome Atlas; DKFZ, Deutsches Krebsforschungszentrum.
See this image and copyright information in PMC

References

    1. Louis DN, Perry A, Wesseling P, et al. The 2021 WHO classification of tumors of the central nervous system: A summary. Neuro Oncol. 2021;23(8):1231–1251. - PMC - PubMed
    1. Barthel FP, Johnson KC, Varn FS, et al. Longitudinal molecular trajectories of diffuse glioma in adults. Nature. 2019;576(7785):112–120. - PMC - PubMed
    1. Varn FS, Johnson KC, Martinek J, et al. Glioma progression is shaped by genetic evolution and microenvironment interactions. Cell. 2022;185(12):2184–2199.e16. - PMC - PubMed
    1. Kocakavuk E, Anderson KJ, Varn FS, et al. Radiotherapy is associated with a deletion signature that contributes to poor outcomes in patients with cancer. Nat Genet. 2021;53(7):1088–1096. - PMC - PubMed
    1. Touat M, Li YY, Boynton AN, et al. Mechanisms and therapeutic implications of hypermutation in gliomas. Nature. 2020;580(7804):517–523. - PMC - PubMed

Publication types

Substances